
One agent.
Real-world impact.
K Pro, the AI agent for biology, powered by multimodal patient data, for smarter biopharma decision making.
It continuously learns from real-world data, user feedback, and clinical validation. The first agent to connect research to care.
Intelligent orchestration of specialized AI skills
K Pro uses a single intelligent orchestrator that dynamically selects and combines specialized AI skills to solve your challenges across drug discovery and development. Instead of juggling multiple tools, you work with one agent that knows exactly which capabilities to activate.
A decade of pharma AI, packaged
Ten years of proven AI drug discovery expertise, purpose-built for your pipeline
- Built on 10+ years of AI tools for drug discovery & development
- Purpose-built for pharma pipeline challenges
Research-to-care intelligence
AI insights validated by real patients, connecting discovery to clinical reality
- Connects insights across the entire drug development journey, from target discovery to clinical validation
- AI reality check through unique integration with Owkin's patient validation hub
Powered by multimodal patient data
From real multimodal patient data to real world impact
- Interrogate findings and refine hypotheses across multiple data sources and modalities with real patient data
- Access unparalleled biological depth through MOSAIC (2,200+ patients, 6 modalities) and Owkin’s vast patient data network
Learn about our patient data network
Secure, interpretable platform
Deploy confidently: compliant, transparent, and built to connect
- Deploy on your infrastructure with ISO27001, GDPR compliance
- Intelligent orchestration: builds tools and runs analyses, not just retrieval
- Connect your own agents, data, and tools via skills framework and MCP integration
K Pro Documentation
Continuous learning
Building an agent that evolves with every trial, experiment, and patient outcome
- Reinforcement loops: Designed to learn from clinical trials, diagnostic testing, and wet-lab studies
- Real-world data: Patient-derived organoids and clinical outcomes will feed the system regularly, refining predictions and accelerating decisions
- User feedback: Architecture that closes the loop, evolving insights as new data and experimental validation become available
Example Use Cases
Discover how K Pro powers smarter pipeline decisions
K Pro's flexible architecture means it can tackle your specific challenges, even ones we haven't anticipated yet.

Features
FREE
Explore and demo on public data
Professional
+ K Pro Free
Decision-grade analysis on proprietary data
Data access
19 public datasets
MOSAIC subset (60 samples)
MOSAIC subset (60 samples)
Data upload
Usage
Limited
High
Privacy
Logged activity
Untracked usage
Support
Standard
Dedicated onboarding & Account Manager
Deployment
SaaS access only
Trusted by top biopharma and researchers

“Its ability to rapidly analyze and visualize complex patient data, including spatial omics, delivers insights in moments. It’s a game-changer.”
Pr. Fabrice André
Head of Research Division, Institut Gustave Roussy

“K has the potential to set new standards for efficiency in biomedical research, by streamlining complex data analysis.”
Pr. Franck Bielle
Neuropathologist at APHP, Head of Brain Tumor Heterogeneity Immunity & Therapy research team, Paris Brain Institute

"K makes complex data exploration effortless and enables researchers to efficiently generate new hypotheses."
Pr. Marc Sanson
Head of Neuro Oncology, APHP

“The potential impact for research teams is obvious, in particular thanks to its robust multi-omics patient data exploration capabilities.”
Dr. Ingo Ringshausen
Principal Investigator at University College London & Consultant Haematologist UCLH
Ready to get started?
Discover how K Pro can transform your drug discovery and development. Connect with our team to explore how we can support your specific needs.
*Certain potential users of Owkin K may be subject to anti-gift or anti-bribery regulations based on their profession and jurisdiction. Owkin is collecting all pertinent information from potential users to ensure that anti-gifting and bribery laws are followed across jurisdictions. Owkin reserves the right to restrict access to certain users who are prohibited from accepting them under applicable regulations.













